Related Experiment Video
Updated: Mar 6, 2026
08:17
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
22.1K
Novel agents in classical Hodgkin lymphoma.
Sven Borchmann1, Bastian von Tresckow1
1a German Hodgkin Study Group (GHSG), Department I of Internal Medicine , University Hospital Cologne , Cologne , Germany.
Leukemia & Lymphoma
|March 21, 2017
Summary
Novel treatments like brentuximab vedotin and immune checkpoint inhibitors offer new hope for relapsed or refractory Hodgkin lymphoma patients. This review details their efficacy and safety in clinical trials.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Classical Hodgkin lymphoma (cHL) is a common cancer in young adults, often curable.
- Relapsed/refractory disease, elderly patients, and treatment toxicity remain significant challenges.
- New therapeutic strategies are urgently needed.
Purpose of the Study:
- To provide a comprehensive review of novel agents for Hodgkin lymphoma currently in clinical trials.
- To compare the safety and efficacy of emerging treatments.
- To discuss the impact of these novel agents on various clinical treatment settings.
Main Methods:
- Review of recent and ongoing clinical trials for Hodgkin lymphoma treatments.
- Focus on targeted drug-antibody conjugates and immune checkpoint inhibitors.
- Analysis of safety and efficacy data from evaluated agents.
Main Results:
- Brentuximab vedotin and immune checkpoint inhibitors have shown promise in changing treatment paradigms.
- Emerging substances and concepts are being evaluated for their therapeutic potential.
- Clinical trial data are being compared to assess real-world applicability.
Conclusions:
- Novel agents represent a significant advancement in Hodgkin lymphoma treatment.
- These new therapies offer improved options for patients with relapsed/refractory disease.
- The review highlights the evolving landscape of Hodgkin lymphoma management.
More Related Videos
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Related Concept Videos
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
01:16Primary Lymphoid Organs
16.3K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
16.3K
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
988
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
988
02:49Cancer Therapies
10.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.5K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
698
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
698